Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Emergent BioSolutions

Emergent BioSolutions said on Monday Johnson & Johnson has agreed to pay $50 million to settle claims related to a terminated manufacturing deal for the latter's COVID-19 vaccine.

Emergent, J&J settle COVID vaccine supply deal dispute

Coca-Cola

Realty Income Corp

PepsiCo

Procter & Gamble

Southern Company

Verizon

Diversified income stocks are a smart choice for investors seeking lifelong cash flow. They offer a reliable stream of income from multiple sources and provide stability and growth potential in any market condition.

7 Diversified Income Powerhouses for Lifelong Cash Flow

Johnson & Johnson is locked in a bitter fight with lawyers opposing its third attempt to settle tens of thousands of lawsuits through a controversial bankruptcy-court maneuver. The women alleging J&J's talc products caused their cancer are caught in the crossfire.

The battle over J&J's bankruptcy plan to end talc lawsuits

Johnson & Johnson reported solid first quarter results and is also expecting mid-single digit growth for the full year. The company is facing risks right now, especially from the litigations due to the talc products, and breaking the support line is also a rather bearish sign. But the stock seems slightly undervalued at this point, and Johnson & Johnson is probably a good investment for investors seeking stability and a bond-like investment.

Johnson & Johnson: Remaining A Buy Despite Remaining Risks

Duke Energy

MetLife

Long-term income stocks are a magnet for investors looking for reliable income streams. These stocks are backed by powerful underlying businesses, known for regular quarterly dividends and consistent payout bumps each year.

3 Rock-Solid Income Machines to Hold for Decades

Archer-Daniels-Midland Company

Genuine Parts

When it comes to investing, few assets hold the appeal of undervalued Dividend Aristocrats—companies honored for their consistent dividend payments and resilient business models. This elite group of stocks comprises companies within the S&P 500 index with a distinguished track record of consistently increasing their dividends for at least 25 consecutive years.

3 Dividend Aristocrats Now Cheaper Than During the 2008 Financial Crisis

A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.

J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

Cisco Systems

Chevron

Dow Inc

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to numerous investors

Buy 2 July Dow Dogs And Watch 6

Colgate-Palmolive

Costco

Home Depot

When you're still years away from retirement, you want to ramp up your portfolio to target growth-oriented enterprises. At the same time, there's a lot of comfort and confidence in so-called cash cows.

7 Blue-Chip Cash Cows to Milk for Steady Income

Chipotle

McDonald's

Starbucks

Sanofi

Walmart

Savvy investors must own safe haven stocks that provide stability and growth potential in an unstable economic environment. Recognizing which companies can withstand market declines becomes critical as investors brace for possible adjustments.

7 Safe Haven Stocks to Buy Before the Next Market Correction

Johnson & Johnson's underlying business has a stable long-term outlook and the stock has a low volatility profile, which makes it an ideal platform for selling put options. The company is trading at a highly attractive valuation, which provides a solid margin of error. Selling put options does sacrifice capital appreciation, but with a nearly 10% annualized yield on offer, this opportunity appears to be a win-win to us.

Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return

CARVYKTI ®  is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J. , July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.

CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study

Bristol-Myers

British American Tobacco

Comcast

Campbell Soup

Gilead Sciences

Kinder Morgan

Medtronic

Altria

Pfizer

Polaris

PNC Financial Services

SPDR S&P 500 ETF Trust

Sempra Energy

Toronto-Dominion Bank

U.S. Bancorp

Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential rate of return. In comparison to Morningstar's 10 Best Value Stocks with 10 Best Dividend Stocks, Bristol-Myers stands out as undervalued with a high potential return.

Going Beyond Morningstar's 10 Best Value Stocks List

AbbVie

Essential Utilities

Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have raised their dividends every one of the previous 25 straight years. Dividend growers had 11.7% compound annual returns from 1986 to 2016, while dividend payers had 9.9%.

3 Retirement All-Stars for Steady Growth and Income

High-yield dividend stocks have consistently attracted the attention of Wall Street investors. These stocks not only provide a steady income stream but also offer the potential for capital appreciation.

3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks

AbbVie is a Dividend King poised for growth. Gilead Sciences is a stable, low-risk candidate for investors.

3 Magnificent Stocks Retirees Can Buy and Hold Forever

Aptiv Holdings Ltd

Becton, Dickinson and Co.

Baidu

Dollar Tree

Las Vegas Sands

Undervalued stocks, let's talk about them. Typically, when you come across a list of equities that are supposedly discounted, you're dealing with industry comparisons.

Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.

News for Johnson & Johnson Stock (JNJ)